Wednesday, November 24, 2021 9:38:06 AM
I understand that a similar tote from a previous (2018) SNO was reported here. IMO there are two very big differences between then and now. First, the registered trademark symbol is missing from 2018. Second, NWBO had an active trial open in 2018 and they do not anymore as of 10.5.2020. Before anyone jumps on the UCLA combo trial, it is just that a trial sponsored by LL and the UCLA, not NWBO. There are no active US trials sponsored by NWBO..
Also, regulatory scrutiny over premarket practices dramatically increases once you initiate the process towards approval. If the BLA is rolling, my opinion would be that started when the database was locked. If this is a more standard submission, then it may be that nothing at all has been filed and fear of reprisal remains low.
A question for Senti and others…if DCVax-l (or its alternative name DCVax) is a platform technology and not a vaccine drug therapy, then what exactly is the drug? It seems to me that each individual batch is unique, so it can’t be at the batch level or that would require 6.5 billion BLAs to treat everyone on this earth or 325 million BLAs if we focus on the US market. Not sure how you would test efficacy in each of those, or recover a fee for delivery of the product. Recall also that the ABTA ad says Brain Tumor on the page so, I believe that clarifies which version of the process they are referring to when they call themselves an immune therapy. To laymen, lung cancer is lung cancer it does not matter what cell type and brain tumors are brain tumors.
I have a lot of angst about all of this too. As with all legal arguments, it is subject to interpretation. But unlike most legal situations, it is not a judge or jury of peers that decides. It is FDA.
Now, I must go and may not read a single post until Sunday evening.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
